(Source: Addex Therapeutics Ltd) Addex ADX71441 Demonstrates Positive Results in Highly Translational Preclinical Model of Spasticity. Geneva, Switzerland, 27 July 2016- Addex Therapeutics (SIX: ADXN) announced today that ADX71441, a positive allosteric modulator (PAM) of the GABAB receptor demonstrated positive results in a highly translational preclinical model of spasticity. The results were obtained at a specialist in vivo pharmacology research organization, NSrepair, in Marseille, France, under the supervision of Dr. Philippe Marino. ADX71441 was evaluated in a leading model of muscle spasticity, the rat transection spinal cord injury (SCI) model. Muscle hyperactivity was measured by a...
↧